- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Inhaled Triple Therapy including corticosteroids Reduces All-Cause Mortality in COPD
China: A new study published in the Chest Journal found that inhaled therapy containing inhaled corticosteroids (ICSs) can reduce the risk of all-cause mortality in patients with Chronic Obstructive Pulmonary Disease (COPD).
Inhaled corticosteroids (ICSs) have been a common maintenance therapy for COPD, but it remains uncertain if their use reduces the all-cause mortality risk and which patient subgroups may benefit. This raises the question of whether inhaled therapy containing ICSs can decrease mortality risk in patients with COPD compared to other therapies.
The study searched multiple databases (PubMed, Cochrane Library, Embase, and ClinicalTrials.gov) for relevant randomized clinical trials (RCTs) and used Peto odds ratios with corresponding 95% confidence intervals to calculate pooled results. The study analysed data from 60 RCTs with over 100,000 COPD patients.
The study concluded with the following clinical findings:
- 1.Inhaled therapy containing ICSs, especially triple therapy, was associated with a lower all-cause mortality risk.
- 2.Subgroup analyses revealed that longer treatment duration, medium/low-dose ICSs, and budesonide were involved in this association.
- 3.The predictors of this association included eosinophil counts of ≥ 200/μL or percentage of ≥ 2%, documented history of ≥ 2 moderate and severe exacerbations in the previous year, Global Initiative for Chronic Obstructive Lung Disease stages III or IV, age younger than 65 years, and BMI of ≥ 25 kg/m2.
- 4.Eosinophil counts of ≥ 200/μL were found to be the strongest predictor.
The study has certain limitations to be acknowledged, such as the fact that it solely relied on data from randomized clinical trials, which may not accurately represent the actual scenario. Furthermore, the possible adverse effects of ICSs were not considered in the study.
According to the researchers of the study, “The findings of the study could help healthcare professionals make better treatment decisions for COPD patients. The study highlights the importance of considering medication factors and patient characteristics when determining the appropriate treatment for COPD patients.”
Reference:
Chen H., Xu Deng Z., Sun J., et al; Association of Inhaled Corticosteroids With All-Cause Mortality Risk in Patients With COPD- A Meta-analysis of 60 Randomized Controlled Trials; CHEST VOLUME 163, ISSUE 1, P100-114,2023; DOI: https://doi.org/10.1016/j.chest.2022.07.015
Dr. Mahalakshmi Sivashankaran joined Medical Dialogues as an Intern in 2023. She is a BDS graduate from Manipal College of Dental Sciences, Mangalore Batch 2022, and worked as a Junior Resident at VMMC & Safdarjung Hospital at the Department of Dental Surgery till January 2023. She has completed a Diploma in Executive Healthcare management from the Loyola Institute of Business Administration, developing skills in Healthcare Management and Administration. She covers several medical specialties including Dental, ENT, Diagnostics, Pharmacology, Neurology, and Cardiology.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751